WALTHAM, Mass., Oct. 30, 2014 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a leader in the development of new therapies to treat neuropsychiatric diseases and disorders, today announced that it will release third quarter financial results after market close on Thursday, November 6, 2014. Minerva management will host a webcast and conference call the same day at 4:30 p.m. EST to discuss the financial results and business highlights.
The live call may be accessed by dialing (877) 312-5845 for domestic callers or (765) 507-2618 for international callers, and by referencing conference ID number 27580305. A live webcast of the conference call will be available online from the investor relations section of the company's website at http://ir.minervaneurosciences.com/. The webcast will be archived on the company website for 30 days.
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat neuropsychiatric diseases. Minerva is developing a portfolio of first-in-class proprietary compounds, including lead compound MIN-101, which is in Phase 2 trials for schizophrenia, and additional candidates targeting major depressive disorder (MDD), insomnia and other CNS disorders. Minerva's common stock is listed on the NASDAQ Global Market where it trades under the symbol "NERV." For more information, please visit www.minervaneurosciences.com/.
CONTACT: Media Contact: Jen Ringler Berry & Company Public Relations Tel: 212-253-8881 firstname.lastname@example.org Investor Contact: Renee Leck Stern Investor Relations Tel: 212-362-1200 email@example.comSource:Minerva Neurosciences, Inc